Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai(University of Michigan), Shaomeng Wang(University of Michigan), Jeanne A. Stuckey(University of Michigan), Jennifer L. Meagher(University of Michigan), Ester Fernández‐Salas, Shunqiang Li(Washington University in St. Louis), Matthew J. Ellis(University of California, Davis), Bing Zhou, Donna McEachern(University of Michigan), Yali Dou(University of Southern California), Daniel F. Hayes(University of Michigan–Ann Arbor), Duxin Sun(University of Michigan), Liu Liu(Shanxi Medical University), Yu‐Jun Zhao(Northwestern University), Fuming Xu, Bo Wen(Monash University), Hui Jiang(Chengdu University of Traditional Chinese Medicine), Jiao Ji(Sun Yat-sen University), Jing Xu(Minzu University of China), Chao‐Yie Yang, Jiantao Hu, Sally Przybranowski
Cited by 0
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k